comparemela.com

Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023

Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Japan ,Bangkok ,Krung Thep Mahanakhon ,Thailand ,United States ,Nivi Nehra ,Naomi Eichenbaum ,World Congress ,Exchange Commission ,Company Annual Report On Form ,Travere Therapeutics Inc ,Nasdaq ,Bits Association ,European Union ,Corporate Communications ,Travere Therapeutics ,Clinical Meetings ,Dual Endothelin Angiotensin Receptor Antagonist ,Reduces Proteinuria ,Interim Results ,Late Breaking Clinical ,Plenary Hall ,Patient Baseline Characteristics ,Asian Regions ,Young Patients ,Sustained Proteinuria Reduction ,Sparsentan Treatment ,Label Extension ,Disease Progression ,Iga Nephropathy ,United Kingdom National Radar Iga Nephropathy ,Important Safety ,Endothelin Receptor Antagonists ,Upper Limit ,Fetal Toxicity ,Kidney Injury ,Angiotensin System ,Acid Reducing Agents ,Steroidal Anti Inflammatory Agents ,Including Selective ,Increasing Serum Potassium ,Reproductive Potential ,Full Prescribing Information ,Private Securities Litigation Reform Act ,Annual Report ,

comparemela.com © 2020. All Rights Reserved.